Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Evaluation of survival by ADCC status: Subgroup analysis of SB3 (Trastuzumab Biosimilar) and reference trastuzumab in patients with HER2-positive early breast cancer at three-year follow-up. Pivot, X., Pegram, M. D., Cortes, J., Luftner, D., Lyman, G. H., Curigliano, G., Bondarenko, I., Yoon, Y., Kim, Y., Lim, J. AMER SOC CLINICAL ONCOLOGY. 2019
View details for DOI 10.1200/JCO.2019.37.15_suppl.580
View details for Web of Science ID 000487345803573